Prometheus Validates Anser VDZ Assay for Use in IBD Patients

Prometheus Validates Anser VDZ Assay for Use in IBD Patients
Prometheus Laboratories has validated its novel Prometheus Anser VDZ assay to monitor adult patients with inflammatory bowel diseases (IBD), including patients with moderate-to-severe active ulcerative colitis (UC) and Crohn’s disease (CD) who are being treated with Entyvio (vedolizumab). “Prometheus Anser VDZ uniquely measures both serum drug concentrations and antidrug antibody levels of vedolizumab from a

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *